[Vaccines against Herpes zoster: Effectiveness, safety, and cost/benefit ratio].

CONCLUSION: Despite controversy and few uncertainties, the vaccine significantly reduces herpes zoster and its complication incidence. In terms of public health objectives, it reduces the burden of the disease and has a positive medico-economic impact. Preliminary data concerning the adjuvanted vaccine, whilst very promising, are still too limited. Up to now, no group of people with particularly high risk of herpes zoster-related complication who will beneficiate the most of the vaccination has been identified yet and only an age criteria has been considered for the recommendation. PMID: 26724874 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/26724874?dopt=Abstract

Source: Presse Medicale - December 24, 2015 Category: Journals (General) Authors: Ferahta N, Achek I, Dubourg J, Lang PO Tags: Presse Med Source Type: research